A Study of Indinavir Sulfate Given Together With Stavudine to HIV-Positive Patients
Not Applicable
Completed
- Conditions
- HIV Infections
- Registration Number
- NCT00002354
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
The purpose of this study is to see if it is safe and effective to give indinavir sulfate plus stavudine to HIV-infected patients who have already been treated with zidovudine.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 540
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of indinavir sulfate and stavudine in HIV treatment?
How does the combination of indinavir sulfate and stavudine compare to standard antiretroviral therapies in HIV-1 patients?
Which biomarkers indicate optimal patient selection for indinavir sulfate plus stavudine therapy in HIV infections?
What adverse events are associated with indinavir sulfate and stavudine combination therapy in HIV-positive individuals?
Are there alternative protease inhibitor and nucleoside reverse transcriptase inhibitor combinations to indinavir sulfate plus stavudine in HIV treatment?
Trial Locations
- Locations (1)
Merck & Co Inc
🇺🇸Whitehouse Station, New Jersey, United States
Merck & Co Inc🇺🇸Whitehouse Station, New Jersey, United States